Kyorin’s OAB Drug Vibegron and More Clear MHLW Panel; Official Nod Anticipated September

A key health ministry panel on August 30 recommended a batch of new medicines including Kyorin Pharmaceutical’s overactive bladder (OAB) treatment vibegron, licensed from US Merck, which could snag approval as early as next month if all goes well. The...read more